肿节风注射液联合阿帕替尼治疗晚期胃癌的临床研究

Clinical study on Zhongjiefeng Injection combined with apatinib in treatment of advanced gastric cancer

目的探讨肿节风注射液联合阿帕替尼治疗晚期胃癌的临床疗效。方法回顾性分析2012年2月—2016年9月在安阳市第五人民医院治疗的46例晚期胃癌患者的临床资料,根据治疗方案的差别分成对照组(23例)和治疗组(23例)。对照组患者于术后餐后30 min口服甲磺酸阿帕替尼片,850 mg/次,1次/d。治疗组在对照组的基础上静脉滴注肿节风注射液,4 m L/次,1次/d。两组患者均治疗4周。比较两组患者治疗前后临床疗效、生存质量和血清学指标改善情况。结果治疗后,对照组客观缓解率(ORR)和临床获益率(CBR)分别为39.13%、47.83%,均显著低于治疗组的65.22%和78.26%,两组比较差异具有统计学意义(P<0.05)。治疗后,对照组和治疗组的生存质量改善率分别为69.57%和91.30%,两组比较差异具有统计学意义(P<0.05)。治疗后,两组患者血清血管内皮细胞生长因子(VEGF)、S100A4、基质金属蛋白酶2(MMP-2)水平均显著降低,而IL-12和γ-干扰素(IFN-γ)水平显著升高,同组比较差异具有统计学意义(P<0.05);且治疗组上述血清学指标变化水平显著优于对照组,两组比较差异具有统计学意义(P<0.05)。结论肿节风注射液联合阿帕替尼治疗晚期胃癌的临床效果显著,可有效改善患者生活质量和提高机体免疫力,具有一定的临床推广应用价值。

Objective To investigate the clinical effect of Zhongjiefeng Injection combined with apatinib in treatment of advanced gastric cancer. Methods The clinical data of patients （46 cases） with advanced gastric cancer in the Fifth People＇s Hospital of Anyang from February 2012 to September 2016 were retrospectively analyzed and divided into control （23 cases） and treatment （23 cases） groups based on different treatments. Patients in the control group were postoperative po administered with Apatinib Mesylate Tablets 30 m after meal, 850 mg/time, once daily. Patients in the treatment group were iv administered with Zhongjiefeng Injection on the basis of the control group, 4 mL/time, once daily. Patients in two groups were treated for 4 weeks. After treatment, the improvement of clinical efficacy, quality of life, and serological indexes in two groups before and after treatment were compared. Results After treatment, the ORR and CBR in the control group was 39.13% and 47.83%, which were significantly lower than 65.22% and 78.26%in the treatment group, respectively, and there were differences between two groups （P 〈 0.05）. After treatment, the quality of life improvement rate in the control and treatment groups were 69.57% and 91.30%, respectively, and there was difference between two groups （P 〈 0.05）. After treatment, the VEGF, S100A4, and MMP-2 levels in two groups significantly decreased, but IL-12 and IFN-γlevels increased, and the difference was statistically significant in the same group （P 〈 0.05）. And the change of these serological indexes in the treatment group was significantly better than that in the control group, with significant difference between two groups （P 〈 0.05）. Conclusion Zhongjiefeng Injection combined with apatinib has significant clinical effect in treatment of advanced gastric cancer, can effectively improve the life quality and immunity, which has a certain clinical application value.